Literature DB >> 20181780

Estimating the personal cure rate of cancer patients using population-based grouped cancer survival data.

Ram C Tiwari, Eric J Feuer.   

Abstract

Cancer patients are subject to multiple competing risks of death and may die from causes other than the cancer diagnosed. The probability of not dying from the cancer diagnosed, which is one of the patients' main concerns, is sometimes called the 'personal cure' rate. Two approaches of modelling competing-risk survival data, namely the cause-specific hazards approach and the mixture model approach, have been used to model competing-risk survival data. In this article, we first show the connection and differences between crude cause-specific survival in the presence of other causes and net survival in the absence of other causes. The mixture survival model is extended to population-based grouped survival data to estimate the personal cure rate. Using the colorectal cancer survival data from the Surveillance, Epidemiology and End Results Programme, we estimate the probabilities of dying from colorectal cancer, heart disease, and other causes by age at diagnosis, race and American Joint Committee on Cancer stage.

Entities:  

Mesh:

Year:  2010        PMID: 20181780      PMCID: PMC2888754          DOI: 10.1177/0962280209347046

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  11 in total

1.  Semiparametric regression analysis of interval-censored data.

Authors:  E Goetghebeur; L Ryan
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

2.  Estimation in the cox proportional hazards model with left-truncated and interval-censored data.

Authors:  Wei Pan; Rick Chappell
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

3.  A review and critique of some models used in competing risk analysis.

Authors:  M Gail
Journal:  Biometrics       Date:  1975-03       Impact factor: 2.571

4.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

Review 5.  Competing risks in mortality analysis.

Authors:  C L Chiang
Journal:  Annu Rev Public Health       Date:  1991       Impact factor: 21.981

Review 6.  Multiple imputation in health-care databases: an overview and some applications.

Authors:  D B Rubin; N Schenker
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

7.  Application of the theory of finite mixtures for the estimation of 'cure' rates of treated cancer patients.

Authors:  N H Gordon
Journal:  Stat Med       Date:  1990-04       Impact factor: 2.373

8.  A proportional hazards model for interval-censored failure time data.

Authors:  D M Finkelstein
Journal:  Biometrics       Date:  1986-12       Impact factor: 2.571

9.  Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival.

Authors:  K A Cronin; E J Feuer
Journal:  Stat Med       Date:  2000-07-15       Impact factor: 2.373

10.  Probabilities of death from breast cancer and other causes among female breast cancer patients.

Authors:  Catherine Schairer; Pamela J Mink; Leslie Carroll; Susan S Devesa
Journal:  J Natl Cancer Inst       Date:  2004-09-01       Impact factor: 13.506

View more
  4 in total

Review 1.  Osteoporosis and musculoskeletal complications related to therapy of breast cancer.

Authors:  Johanna Suskin; Charles L Shapiro
Journal:  Gland Surg       Date:  2018-08

2.  A transformation class for spatio-temporal survival data with a cure fraction.

Authors:  Sandra M Hurtado Rúa; Dipak K Dey
Journal:  Stat Methods Med Res       Date:  2012-04-18       Impact factor: 3.021

3.  The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival.

Authors:  Libby Ellis; Aurélien Belot; Bernard Rachet; Michel P Coleman
Journal:  J Glob Oncol       Date:  2019-05

4.  Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study.

Authors:  Jihyoun Lee; Heba M Alqudaihi; Michael Seungcheol Kang; Jisun Kim; Jong Won Lee; Beom Seok Ko; Byung Ho Son; Sei Hyun Ahn; Jong Eun Lee; Sun Wook Han; Zisun Kim; Sung Mo Hur; Ji Sung Lee; Il Yong Chung
Journal:  Front Oncol       Date:  2020-03-20       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.